ArticleScientific reports2017
Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.Bioscience reports · 2020Pooled it
- Clinical significance of miRNAs and exosomal miRNAs in non-small cell lung cancer: diagnostic, prognostic, and therapeutic perspectives.Journal of human genetics · 2026Review
- Graphene Oxide (GO) and Gold Nanoparticles (AuNP) Facilitated Electrochemical Biosensing for Lung Cancer Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Urinary Profiles of Exosomal LINE-1 mRNA and Associated miRNAs in Non-Small-Cell Lung Cancer.Cells · 2026Article
- Review
- In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma.Molecular oncology · 2026Article
- From immune desert to hot tumor: the tripartite synergy of tumor microenvironment-exosomes-immunogenic cell death in pioneering solutions.Frontiers in immunology · 2026Review
- Blood-Based miRNA Panels for Timely Detection of Non-Small-Cell Lung Cancer: From Biomarker Discovery to Clinical Translation.International journal of molecular sciences · 2025Review
- Past, present, and future of exosomes research in cancer: A bibliometric and visualization analysis.Human vaccines & immunotherapeutics · 2025Article
- Exosomal microRNAs: A new role in the diagnosis and treatment of lung cancer metastases (Review).International journal of oncology · 2025Review
- Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment.Translational lung cancer research · 2025Review
- Effects of small extracellular vesicles isolated from pleural effusion on lung cancer cell proliferation and migration.Human cell · 2025Article
- Circulating Molecular Biomarkers for the Diagnosis and Monitoring of NSCLC-A Review.International journal of molecular sciences · 2025Review
- HypoxamiRs: the hidden architects of tissue adaptation in hypoxia.Cell death & disease · 2025Review
- Breaking barriers: Smart vaccine platforms for cancer immunomodulation.Cancer communications (London, England) · 2025Review
- Exosomal Biomarkers: A Comprehensive Overview of Diagnostic and Prognostic Applications in Malignant and Non-Malignant Disorders.Biomolecules · 2025Review
- Proteomic profiles screening identified novel exosomal protein biomarkers for diagnosis of lung cancer.Clinical proteomics · 2025Article
- MiRNA-Based Exosome-Targeted Multi-Target, A Multi-Pathway Intervention for Personalized Lung Cancer Therapy: Prognostic Prediction and Survival Risk Assessment.Iranian journal of biotechnology · 2025Article
- Research trends in microRNA profiling as a biomarker for lung adenocarcinoma via liquid biopsy: A bibliometric analysis.Narra J · 2025Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the leading causes of cancer-related deaths. It is diagnosed mostly at the locally advanced or metastatic stage. Recently, micro RNAs (miRs) and their distribution in circulation have been implicated in physiological and pathological processes. In this study, miR-126 was evaluated in serum, exosome and exosome-free serum fractions in non-small cell lung cancer (NSCLC) patients at early and advanced stages, and compared with healthy controls. Down-regulation of miR-126 was found in serum of advanced stage NSCLC patients. In healthy controls, circulating miR-126 was equally distributed between exosomes and exosome-free serum fractions. Conversely, in both early and advanced stage NSCLC patients, miR-126 was mainly present in exosomes. Different fractions of miR-126 in circulation may reflect different conditions during tumour formation. Incubation of exosomes from early and advanced NSCLC patients induced blood vessel formation and malignant transformation in human bronchial epithelial cells. On the other hand, exosome-enriched miR-126 from normal endothelial cells inhibited cell growth and induces loss of malignancy of NSCLC cells. These findings suggest a role of exo-miRs in the modulation of the NSCLC microenvironmental niche. Exosome-delivered miRs thus hold a substantial promise as a diagnostics biomarker as well as a personalized therapeutic modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.